What Celon Laboratories does

Celon Laboratories Private Limited is a Hyderabad-based specialty biopharmaceutical company founded in 2007 that develops, manufactures, and markets injectable formulations across oncology and critical care. The company operates two branded verticals, Vivilon (oncology, 2007) and Revilon (critical care, 2009), and distributes through hospital pharmacies, government health programs, and COVID-19 treatment centers in India and 46+ export markets. Its commercial model is product-based B2B sales of sterile injectables through 640+ distribution channels, with no disclosed software, subscription, or recurring service revenue component.

Celon's R&D platform is built around proprietary Novel Drug Delivery Systems (NDDS) spanning liposomal, microsphere, and nanoparticulate formulations designed to improve pharmacokinetics and reduce toxicity of active pharmaceutical ingredients. Manufacturing is concentrated at the Hyderabad facility, with a planned greenfield expansion of approximately Rs 200 crore explicitly targeted at regulated markets including the US and EU. The portfolio spans 650+ product registrations across 46+ countries, indicating a multi-year cumulative investment in country-specific regulatory filings, bioequivalence data, and inspections.

In 2020, a 74% controlling stake was acquired by ZNZ Pharma 2—a vehicle backed by CDC Group, Development Partners International, and EBRD—for Rs 364 crore at a Rs 485 crore enterprise valuation. Reported FY2020 revenue was Rs 200 crore with a management projection of Rs 250 crore in FY2021, implying approximately 25% YoY growth. The combination of institutional DFI sponsorship, planned capacity expansion, and managed revenue scaling positions Celon as a growth-stage specialty injectables platform targeting emerging and regulated geographies, led by Ajay Bhatia as Chairman and Managing Director.

Name

Celon Laboratories

Legal name

Celon Laboratories Private Limited

Website

https://celonlabs.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Celon Laboratories is a Hyderabad-based specialty biopharmaceutical company founded in 2007 that develops injectable formulations for oncology and critical care using novel drug delivery technologies, operating two brands — Vivilon and Revilon — and serving hospital, government, and distributor channels across 46+ countries.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (42421)

SIC

Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industry

CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• Oncology pharmaceuticals
• Critical care drugs
• Specialty injectables
• Contract manufacturing
• Novel drug delivery systems

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Formulation Product Sales - India: Domestic sales of branded formulations in Oncology (Vivilon) and Critical Care (Revilon) therapy areas through field sales force and institutional sales
2. International Branded/Tender Sales: Sales of branded generic formulations to ROW markets (LATAM, Africa, CIS, SEA) through distributor network and government tender business
3. Contract Manufacturing (CMO): Manufacturing services for Oncology and Critical Care products for third-party clients

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Celon Laboratories manufactures and markets specialty pharmaceutical formulations focused on oncology (under the Vivilon brand) and critical care (under the Revilon brand). The company offers injectables and other dosage forms developed using proprietary Novel Drug Delivery Systems (NDDS) platforms, serving domestic Indian hospitals, government health institutions, and over 46 international markets. It also provides contract manufacturing services for injectables at its WHO-GMP and Schedule M certified Hyderabad facility.

Product overview

Celon Laboratories is a pharmaceutical company offering two main sub-brands: Vivilon (Oncology, launched 2007) and Revilon (Critical Care, launched 2009). The Vivilon portfolio includes cytotoxic chemotherapy agents (paclitaxel, docetaxel, gemcitabine, platinum-based drugs), targeted therapies (gefitinib, erlotinib), monoclonal antibodies (bevacizumab, trastuzumab, rituximab), hormonal therapies (tamoxifen, letrozole, abiraterone), and supportive care medications. The Revilon Critical Care portfolio provides injectable medications including anesthetics (propofol, etomidate), neuromuscular blockers (atracurium, vecuronium), cardiovascular drugs (anticoagulants, vasopressors, inotropes), anti-infectives (antibiotics, antifungals, antivirals), and ICU therapies (corticosteroids, antioxidants). The company also offers advanced formulations including liposomal drug delivery (Liposomal Doxorubicin, Amphotericin B Liposome), nanoparticle technology (NAB Paclitaxel), and emulsion formulations (Amphotericin B Emulsion).

Differentiator

Problem solved

Functional benefit

Brands

• Vivilon: Celon's specialized oncology offering launched in 2007, helping cancer patients with products for solid tumor, hematology, and supportive care. Includes India's first Bone Marrow Transplantation range.
• Revilon

Products and services

• Vivilon Celon's oncology product brand under which a wide range of anti-cancer injectables and formulations are marketed to hospitals, oncologists, and cancer treatment centers in India and international markets.
• Revilon Celon's critical care product brand covering anti-infectives, anesthetics, and other ICU/emergency injectable formulations supplied to hospitals and critical care units.
• Contract Manufacturing Services Third-party contract manufacturing services for sterile injectables and formulations at Celon's WHO-GMP and Schedule M compliant manufacturing facility, offered to pharmaceutical companies needing outsourced manufacturing capacity.
• GEFTILON (Gefitinib) Tablets containing gefitinib used in the treatment of non-small cell lung cancer, marketed to oncology specialists and hospitals.
• CELZAR (Gemcitabine) Injectable gemcitabine formulation used in chemotherapy regimens for various cancers, supplied to oncology hospitals and infusion centers.
• CABOZANIB (Cabozantinib) Oral cabozantinib tablets used in the treatment of renal cell carcinoma and other cancers, marketed to oncology specialists.
• CELHEP (Heparin Sodium) Heparin sodium injection used as an anticoagulant in critical care, dialysis, and surgical settings, supplied to hospitals and ICUs.
• CELPAN (Pantoprazole) Pantoprazole injectable used for acid-related critical care indications in ICU and hospital settings.
• CELNOCID (Glycopyrrolate) Glycopyrrolate injection used in anesthesia and critical care, supplied to hospitals and surgical centers.
• CEFNIL-S (Ceftriaxone + Sulbactam) Injectable combination of ceftriaxone and sulbactam used as a broad-spectrum anti-infective in hospital and critical care settings.
• SALBAZOL (Salbutamol) Salbutamol inhalation/respiratory product used for bronchodilation in critical care and emergency settings.
• CELCORT (Hydrocortisone) Hydrocortisone injection used as a corticosteroid in critical care, emergency, and hospital settings.
• CELODOPA (Dopamine)

Quantifiable outcome

• 10,000 vials per day production capacity for Amphotericin B Emulsion, providing treatment for approximately 6,000 patients monthly
• +1 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Three partnerships are on record, tiered minor.

• Akshaya Patra FoundationminorOthers · 1 January 2021Celon partnered with Akshaya Patra Foundation under its COVID FEEDING PROGRAM to feed families of government school children during the pandemic. CSR initiative supporting underprivileged children.
• Surge Impact FoundationminorOthers · 1 January 2021Celon partnered with Surge Impact Foundation for the Haritha Haram Program (environmental sustainability) and First Job Fellowship program (skill development for underprivileged youth). CSR initiatives focused on environmental protection and employment opportunities.
• Citadel Management ConsultingminorOthers · 1 January 2020Hyderabad-based mid-market investment banking firm that advised Celon on the ZNZ Pharma transaction. One-time advisory engagement for the acquisition deal.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Natco Pharma: Indian specialty pharmaceutical company focused on oncology and complex generics with strong ROW and US franchise. Highly comparable to Celon in oncology formulation focus, injectable capabilities, and ROW tender business model.
• Shilpa Medicare: Indian specialty pharma with oncology formulations, APIs, and novel drug delivery systems including liposomal and nanoparticle platforms. Direct comparability with Celon's oncology focus and NDDS technology stack.
• Hetero Drugs: Indian pharmaceutical company with major oncology and critical care franchises plus large global generics footprint. Comparable in cytotoxic manufacturing capabilities, ROW market presence, and PE-backing history.

Broad incumbents

• Dr. Reddy's Laboratories: Large Indian multinational pharma with significant oncology and critical care portfolios plus established US/EU presence. Comparable in oncology injectables and emerging-market focus, though broader and larger scale.
• Cipla: Major Indian pharma with critical care (including Amphotericin B franchise) and oncology portfolios plus strong ROW presence. Comparable critical care injectable focus, though far larger and more diversified.
• Aurobindo Pharma: Indian pharmaceutical manufacturer with substantial sterile injectable and oncology generic franchise, strong regulatory approvals across emerging markets. Comparable in cytotoxic manufacturing and ROW tenders, though far larger scale.
• Biocon: Indian biopharmaceutical company with leading biosimilars (oncology) and complex injectables franchise. Overlaps with Celon in oncology injectables and novel drug delivery platforms.
• Glenmark Pharmaceuticals: Indian specialty pharma with oncology and critical care segments. Comparable in specialty formulation focus and ROW presence, though broader portfolio.
• Fresenius Kabi: Global leader in sterile injectable pharmaceuticals including oncology and critical care with WHO-GMP facilities worldwide. Comparable in injectable cytotoxic manufacturing and hospital-channel critical care products.

Regional players

• Strides Pharma Science: Indian pharmaceutical company focused on complex generics, sterile injectables, and ROW markets. Comparable in sterile injectable capabilities, WHO-GMP certifications, and emerging market distribution networks.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCOx8b92G7fKL17ctYRaYPmw
• Facebookfacebook.com/Celonlaboratories
• LinkedInlinkedin.com/company/celon-laboratories-limited
• Xx.com/celonlabs

Compliance16 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celon Laboratories